$ARDX

Foster Eric Duane sold $33K of ARDX

Foster Eric Duane (Chief Commercial Officer) sold 8,562 shares of ARDELYX, INC. (ARDX) at $3.86 across 3 trades on 2026-08-21.

Original reporting
SEC EDGAR · Foster Eric Duane
Published Aug 25, 2026, 11:13 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 25, 2026, 11:22 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ARDX
Neutral
high confidence
Mentioned
$ARDX
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ARDXNeutralLow
01

Why it matters

The disclosed sale is modest and unlikely to move the stock price, but it provides transparency for investors monitoring insider activity.

02

Market read

Insider transaction of modest size; limited trading relevance.

03

What to watch

Potential tax‑loss harvesting or portfolio rebalancing could be the motive, not company fundamentals.

Relevance 3/10Novelty 4/10Timing: filed 2026-08-25

Background

Form 4 filings disclose insider trades; a sale by a senior officer is routinely reported.

Company-level read

Ticker impact

$ARDXNeutralHigh confidence
Context

Chief Commercial Officer sold 8,562 shares for $33,023 in a Form 4 filing.

Expected impact

No material price impact expected.

Evidence & confidence

The transaction amount is small relative to holdings and market cap; typical for routine diversification.

Market effects

None; insider sale does not affect sector outlook.

None; company is US‑based with limited regional relevance.

Minimal; isolated insider transaction.

Counterpoint

If the insider is offloading shares ahead of undisclosed negative news, the sell could foreshadow a downside.

Key entities

  • Foster Eric Duane

    Chief Commercial Officer of ArdeLyx, Inc.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ARDXMedAI 8/10

Ardelyx (ARDX) Q2 2026 Earnings Call Transcript

Ardelyx (ARDX) reported Q2 2026 product revenue of $118.1 million, up 31% year over year, driven by IBSRELA ($86.2 million, +33%) and XPHOZAH ($31.9 million, +27%). Net loss was $16.7 million. The company revised 2026 guidance to $350-$370 million for IBSRELA and $110-$120 million for XPHOZAH, citing payer hurdles.

$ARDXHighAI 9/10

Why is Ardelyx stock plunging today?

Ardelyx (ARDX) shares fell about 16% pre-open after the company reported Q2 2026 results that missed Wall Street on revenue and EPS and cut full-year guidance. Q2 total product revenue was $118.1M, net loss $16.7M (-$0.07/share). Ardelyx lowered 2026 IBSRELA revenue guidance to $350–$370M and withdrew a prior XPHOZAH long-term target.

$ARDXMed

ARDELYX, INC. (ARDX): Results of Operations and Financial Condition

ARDELYX, INC. (ARDX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Ardelyx Reports Second Quarter 2026 Financial Results and Provides Business Update Q2 2026 total product revenue of $118.1 million, reflecting 31% growth year-over-year IBSRELA Q2 2026 revenue growth of 33% year-over-year to $86.2 million XPHOZAH Q2 2026 revenue grow